secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2023-02-10T23:59:59+00:00
Accession:  0001370053-23-000013
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio adopts amended bylaws to align with DGCL changes and universal proxy rules
--------------------------------------------------------------------------------

- Board approved Second Amended and Restated Bylaws effective Feb 7, 2023; updates advance notice, proxy procedures, and exclusive forum clause.
- Amendments conform to 2022 DGCL changes on adjournment, stockholder lists, and electronic notices; adds emergency bylaw provision.
- Enhanced stockholder nomination requirements: limits nominees to board seats, mandates compliance with SEC Universal Proxy Rules (Rule 14a-19).
- Exclusive forum clause designates federal district courts for Securities Act claims unless company consents otherwise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000013/0001370053-23-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000013/anab-20230207.htm
  HTML page:      https://secwatch.observer/filing/0001370053-23-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer